Scientists produce malaria vaccine from algae

Image
IANS New York
Last Updated : Feb 19 2015 | 5:00 PM IST

Researchers have developed a new candidate for malaria vaccine with the help of algae-produced malaria parasite protein.

Paired with an immune-boosting cocktail suitable for use in humans, the algae-produced protein generated antibodies in mice that nearly eliminated mosquito infection by the malaria parasite.

Besides its effectiveness as a protein producer, algae is an advantageous tool for developing vaccines because it is cheap, easy and environmentally friendly.

"Most malaria vaccine approaches are aimed at preventing humans from becoming infected when bitten by mosquitoes that carry the parasite," said senior author of the study Joseph Vinetz, professor of medicine at the University of California (UC), San Diego School of Medicine.

"Our approach is to prevent transmission of the malaria parasite from infected humans to mosquitoes," Vinetz explained.

The researchers turned to an algae to produce Pfs25, a protein found on the surface of the malaria parasite's reproductive cells. They believed that Pfs25 might block transmission of the parasite to the next host.

They introduced the Pfs25 gene into the algae by shooting the DNA into the plant cell's nucleus.

Then, after they let the algae do the work of replicating, building and folding the protein, the team was able to purify enough functional Pfs25 for laboratory testing.

In experiments, the researchers found that only one of 24 mosquitoes (4.2 percent) that consumed the Pfs25/adjuvant-treated mouse serum was positive for the malaria parasite.

That is compared to the 28 infected mosquitoes out of the 40 in the control group (70 percent).

Adjuvants are molecules that help stimulate the immune system's response to Pfs25.

"We are really excited to see that Pfs25 produced by algae can effectively prevent malaria parasites from developing within the mosquito," study co-author Stephen Mayfield from UC San Diego.

The study was published in the journal Infection and Immunity.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 19 2015 | 4:56 PM IST

Next Story